Free Trial

AbCellera Biologics (ABCL) Earnings Date, Estimates & Call Transcripts

AbCellera Biologics logo
$2.85 +0.14 (+5.17%)
(As of 12/20/2024 05:40 PM ET)

AbCellera Biologics Latest Earnings Summary

Actual EPS
(Nov. 4)
-$0.17 Missed By -$0.03
Consensus EPS
(Nov. 4)
-$0.14

AbCellera Biologics issued Q3 2024 earnings on November 4, 2024, reporting an EPS of -$0.17, which missed analysts' consensus estimates of -$0.14 by $0.03. Quarterly revenue was reported to be $6.51 million, below the consensus estimate of $8.95 million. With a trailing EPS of -$0.61, AbCellera Biologics' earnings are expected to decrease next year, from ($0.59) to ($0.71) per share.

Get AbCellera Biologics Earnings Alerts

Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on AbCellera Biologics and other key companies, straight to your inbox.

Sign Up
Skip Charts & View Estimated and Actual Earnings Data

ABCL Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

ABCL Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

AbCellera Biologics Analyst EPS Estimates

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20243-$0.14-$0.08-$0.11
Q2 20243-$0.15-$0.09-$0.13
Q3 20243-$0.14-$0.05-$0.09
Q4 20243-$0.15-$0.09-$0.11
FY 202412-$0.58-$0.31-$0.45
Q1 20251-$0.15-$0.15-$0.15
Q2 20251-$0.15-$0.15-$0.15
Q3 20251-$0.16-$0.16-$0.16
Q4 20251-$0.17-$0.17-$0.17
FY 20254($0.63)($0.63)($0.63)

AbCellera Biologics Earnings History by Quarter

DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails
11/4/2024Q3 2024-$0.14-$0.17 -$0.03-$0.17$8.95M$6.51M
8/6/2024Q2 2024-$0.15-$0.13+$0.02-$0.13$10.12M$7.30M
5/7/2024Q1 2024-$0.16-$0.14+$0.02-$0.14$10.73M$9.95M
2/20/2024Q4 2023-$0.14-$0.17 -$0.03-$0.17$9.58M$9.18M
11/2/2023Q3 2023-$0.14-$0.10+$0.04-$0.10$11.92M$6.60M
8/3/2023Q2 2023-$0.13-$0.11+$0.02-$0.11$12.38M$10.10M
The #1 Coin for November 2024 (Ad)

Grayscale Investments just announced a new fund offering access to a HOT new DeFi coin… And thanks to this newly established trust, I believe this coin could skyrocket up to 150x+ in the next 30 days alone! I've compiled everything you need to know about this once-in-a-lifetime DeFi project into a brand-new comprehensive guide…

You can get access to the report by clicking here now…
5/4/2023Q1 2023-$0.12-$0.14 -$0.02-$0.14$12.11M$12.20M
2/21/2023Q4 2022$0.01-$0.10 -$0.11-$0.10$50.80M$21.50M

AbCellera Biologics Earnings - Frequently Asked Questions

AbCellera Biologics (NASDAQ:ABCL) last announced its quarterly earning data on Monday, November 4, 2024. Learn more on ABCL's earnings history.

In the previous quarter, AbCellera Biologics (NASDAQ:ABCL) missed the analysts' consensus estimate of ($0.14) by $0.03 with a reported earnings per share (EPS) of ($0.17). Learn more on analysts' earnings estimate vs. ABCL's actual earnings.

The conference call for AbCellera Biologics's latest earnings report can be listened to online.
Listen to Conference Call

The conference call transcript for AbCellera Biologics's latest earnings report can be read online.
Read Transcript

AbCellera Biologics (NASDAQ:ABCL) has a recorded annual revenue of $32.96 million.

AbCellera Biologics (NASDAQ:ABCL) has a recorded net income of -$146.40 million. ABCL has generated -$0.61 earnings per share over the last four quarters.

AbCellera Biologics's earnings are expected to decrease from ($0.59) per share to ($0.71) per share in the next year.

More Earnings Resources from MarketBeat



This page (NASDAQ:ABCL) was last updated on 12/22/2024 by MarketBeat.com Staff
From Our Partners